Imugene Ltd (ASX: IMU, OTC: IUGNF) chief medical officer Dr. Paul Woodard and managing director and CEO Leslie Chong talked with Proactive’s Tylah Tully about the latest results from the Phase 1b clinical trial of Azer-cel, the company’s CD19 CAR-T therapy. Dr. Woodard, speaking from 2025 Tandem Meetings in Honolulu, shared the excitement around the trial's findings. Azer-cel is being developed for patients who have relapsed after multiple lines of treatment. The latest data reveals a 57% complete response rate, meaning no detectable lymphoma in these patients. Chong highlighted that the addition of a low dose of IL-2 to Azer-cel has contributed to T-cell proliferation, helping patients’ immune systems fight back. She emphasised that seeing durable responses in patients who have exhausted multiple treatment options is a significant achievement. Dr. Woodard also underscored the importance of these results, stating that some patients are experiencing long-lasting remissions, with one individual remaining in complete remission for over ten months. These findings reinforce the potential of Azer-cel in addressing an unmet need in relapsed and refractory lymphoma patients. #Imugene #AzerCel #CAR_T #Biotech #Oncology #CancerResearch #ClinicalTrials #Lymphoma #MedicalBreakthrough #Investing